Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M. Gay, Lauren A. Byers, C. Allison Stewart et al.|Cancer Cell|2021Cited by 930
Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent.Vito Quaranta, Soldano Ferrone, L E Walker et al.|The Journal of Immunology|1980Cited by 118
Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancerSarah M. Groves, Vito Quaranta, Alan J. Simmons et al.|Cell Systems|2022Cited by 59
The free and the ?2-microglobulin-associated heavy chains of HLA-A, B alloantigens share the antigenic determinant recognized by the monoclonal antibody Q1/28Vito Quaranta, Soldano Ferrone, L E Walker et al.|Immunogenetics|1981Cited by 58
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLCPortia Thomas, Christine M. Lovly, Sarah M. Groves et al.|Journal of Thoracic Oncology|2021Cited by 33